AstraZeneca: licensing agreement between Alexion and Neurimm

(CercleFinance.com) - Alexion, AstraZeneca's rare disease subsidiary, announced on Friday that it has signed an exclusive licensing agreement with the Swiss biopharmaceutical company Neurimmune.


Under the terms of the agreement, Alexion will obtain worldwide rights to develop, manufacture and commercialise NI006, a monoclonal antibody currently in development.

The product is currently in a Phase Ib trial for the treatment of transthyretin cardiac amyloidosis, a rare and under-diagnosed disease that limits the life expectancy of patients to four years after diagnosis.

NI006 targets abnormal changes in the transthyretin (TTR) protein, removing amyloid deposits that accumulate in the heart and lead to progressive heart dysfunction.


Copyright (c) 2022 CercleFinance.com. All rights reserved.